Status:
COMPLETED
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline ...
Eligibility Criteria
Inclusion
- Diagnosis of glaucoma (primary open angle, pigmentary, exfoliative) or ocular hypertension (IOP \>= 21 mmHG).
- Visual acuity \>= 20/200.
Exclusion
- Closed/barely open anterior chamber angle or history of acute angle closure glaucoma.
- Hystory of ALT within 3 months prior to the baseline visit.
- History of any ocular filtering surgical intervention.
- Ocular surgery or inflammation/infection within 3 months prior to the baseline visit.
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00143208
Start Date
May 1 2003
End Date
April 1 2006
Last Update
February 21 2021
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Arezzo, Italy, 52100
2
Pfizer Investigational Site
Bari, Italy, 74100
3
Pfizer Investigational Site
Bollate, Italy
4
Pfizer Investigational Site
Bologna, Italy, 40133